
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Mission: Extend human healthspan by epigenetically reprogramming aged cells to restore youthful function
Platform: Discovery Engine combining high-throughput functional genomics, single-cell multi‑omics, pooled perturbation screening, and machine learning
Funding (disclosed): $170M across a $40M Series A (May 2023) and $130M Series B (May 2025)
Notable founders: Brian Armstrong, Blake Byers, Jacob C. Kimmel (also listed: Greg Johnson)
Early programs: Liver, immune, and vascular systems
Team size (reported): 34 (as of May 2025)
| Company |
|---|
Age-related disease and loss of cellular function due to epigenetic aging
2022
Biotechnology Research
$40M
Investors included Dimension Capital, Founders Fund, Kleiner Perkins, with participation from angels such as Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam.
$130M
Series B included new investors (e.g., Nat Friedman & Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners) alongside returning backers such as Dimension Capital and Founders Fund and multiple angel investors.
$45M
Described as additional financing including participation from Eli Lilly & Company, Duke Management Company, Section 32, and others.
“Backed by top-tier venture firms (Kleiner Perkins, Founders Fund, Dimension Capital, Khosla Ventures), strategic/corporate investors including Eli Lilly, university management company participation, and numerous prominent angel investors.”
About NewLimit NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Position
NewLimit is seeking an scientist with experience in discovery biology to join our Vascular therapeutic team. Our Vascular program is developing reprogramming medicines to restore youthful function in aged endothelial cells for the treatment of renal, cardiometabolic, and cognitive diseases.
Your role will focus on developing and deploying assays to measure the functional decline that occurs in endothelial cells with age. You will collaborate closely with our technology teams to help create the first reprogramming medicines for the vascular tissue that supports all others.
What you'll do
In Your Role As a Scientist, You Will
Requirements
Nice to have
Benefits NewLimit offers generous benefits to ensure our team can focus on our mission:
Salary Range: $130,000 to $180,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.